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Abstract
Background: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the prodromal
phase of Alzheimer’s disease (Pr-AD). New biomarkers are useful in detecting Pr-AD, but they are not universally
available. We aimed to investigate baseline clinical and neuropsychological variables that might predict progression
from MCI to AD dementia.
Methods: All patients underwent a complete clinical and neuropsychological evaluation at baseline and every 6
months during a two-year follow-up period, with 54 out of 109 MCI patients progressing to dementia (50 of them
progressed to AD dementia), and 55 remaining as stable MCI (S-MCI).
Results: A combination of MMSE and California Verbal Learning Test Long Delayed Total Recall (CVLT-LDTR)
constituted the best predictive model: subjects scoring above 26/30 on MMSE and 4/16 on CVLT-LDTR had a
negative predictive value of 93.93% at 2 years, whereas those subjects scoring below both of these cut-off scores
had a positive predictive value of 80.95%.
Conclusions: Pr-AD might be distinguished from S-MCI at baseline using the combination of MMSE and CVLT-
LDTR. These two neuropsychological predictors are relatively brief and may be readily completed in non-specialist
clinical settings.
Background
Different biomarkers have been thoroughly studied in
order to establish which ones best predict the progres-
sion from mild cognitive impairment (MCI) to Alzhei-
mer’s disease (AD) dementia. With current evidence,
medial temporal lobe and hippocampal atrophy on MRI,
glucose metabolism reduction measured by FDG-PET
and CSF biomarkers reflecting AD pathology, are useful
in detecting prodromal AD (Pr-AD) patients [1]. Never-
theless, these new biomarkers are still not universally
available in routine clinical practice. A neuropsychologi-
cal profile differentiating Pr-AD from stable MCI (S-
MCI) has been investigated, and episodic memory
impairment seems to be a strong predictor of progression
to dementia [2-4], although it is not specific as some
patients will not develop AD. Impairment in other cogni-
tive domains (executive function and language) has been
described in Pr-AD, but there are discrepancies about
which additional impaired area will most improve sensi-
tivity and specificity for detecting Pr-AD [5-7]. We aim
to investigate the clinical variables and neuropsychologi-
cal measures at the moment of MCI diagnosis, which will
better predict the progression from MCI to early AD
dementia in a two-year follow-up period.
Methods
A total of 115 patients (63.3% females; mean age at
diagnosis 74.4 years, SD 6.8; education, 63.3% primary
school) were consecutively recruited from the Memory
Clinic of University Hospital “Marqués de Valdecilla”
(Santander, Spain) between April 2007 and April 2008.
All of them initially fulfilled the Petersen criteria for
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dementia (DSM-IV), AD (NINCDS-ADRDA), depressive
episode (IDC-10), subjects with significative cerebrovas-
cular disease (Hachinski scale score ≥4), and those with
any other medical or psychiatric identifiable cause
accounting for their complaints. All patients underwent
a complete clinical and neuropsychological evaluation at
baseline and every 6 months during a two-year follow-
up period. General cognitive function was assessed
using MMSE, data on activities of daily living were col-
lected using the Interview for Deterioration in Daily liv-
ing activities in Dementia (IDDD), and symptoms of
depression were measured using the Hamilton Rating
Scale for Depression. Neuropsychological battery
included test for the assessment of memory (California
Verbal Learning Test-CVLT), language and semantic
memory (15-items short-form of the Boston Naming
Test, category fluency), praxis and visuospatial skills
(Rey complex figure copy and WAIS block design subt-
est), attention and executive function (Symbol Digit
Modalities Test, Trail Making part A and B, Stroop
interference Test, Frontal Assessment Battery, category
and letter fluency). A cognitive domain was judged as
impaired when subjects scored 1.5 SD below values for
age and education matched controls in at least one test.
According to the results of the neuropsychological
exploration, subjects were classified as: 1/ subjective
memory complaints (SMC), patients performing nor-
mally on neuropsychological examination; 2/ pure
amnestic MCI (a-MCI), patients fulfilling Petersen’sc r i -
teria for amnestic MCI, with memory being the only
affected domain; 3/ multidomain MCI (md-MCI),
patients fulfilling a-MCI criteria and with one or more
non-memory domain performance being under the cut-
off value; 4/ non-amnesic MCI (na-MCI), patients with
intact memory performance but scoring below the cut-
off score on one or more non-memory tests.
The study was approved by the ethical committee of
the University Hospital “Marqués de Valdecilla”,a n d
written informed consent was obtained from all the
patients.
Statistical analyses were performed with SPSS software
v.14.0. Differences in demographic, baseline clinical
characteristics and neuropsychological measures
between groups (S-MCI versus Pr-AD) were determined
using Student’s t-test for quantitative and c
2 for catego-
rical variables. We included in a logistic regression
model all variables associated with disease progression
(p < 0.05), plus gender, age and ApoE e4 status, in
order to select those of them that were independent
predictors of dementia. ROC curve analysis was per-
formed to evaluate the discriminating power of the pre-
dictive model for the progression to dementia. The area
under the curve (AUC) was used as a measure of the
overall performance. Optimum cut-off points of selected
variables were calculated by choosing the point on the
ROC curve that maximized both sensitivity and
specificity.
Results
From the 115 patients included in the study, 6 patients
were missed early in time and they did not complete the
first year of follow-up, so they were excluded. The
patients that ended the follow-up (n = 109) were classi-
fied in MCI subgroups according to their neuropsycho-
logical performance at baseline: 29 a-MCI (27%), 55
md-MCI (50%), 15 na-MCI (14%) and 10 SMC (9%).
During the 2 years follow-up, 54 patients (49.54%) pro-
gressed to dementia, and 55 remained as S-MCI without
progressing to dementia. Two patients were diagnosed
as Lewy bodies dementia (LBD) and two as vascular
dementia (VD), the remaining 50 patients being diag-
nosed as AD dementia. Given the initial classification in
MCI subgroups, 62% (n = 18) of a-MCI and 58% (n =
32) of md-MCI patients evolved to AD dementia,
whereas only 13% (n = 2) of na-MCI patients progressed
to dementia (1 LBD and 1 VD). Among md-MCI sub-
jects, one patient was diagnosed as VD and another was
considered LBD, and none patient evolved to dementia
in the SMC group.
We searched for differences in demographic, past
medical history and neuropsychological assessments at
baseline between S-MCI and Pr-AD (Table 1). Patients
that evolved to non-AD dementia were excluded. In the
univariate analysis, Pr-AD patients were significantly
older than S-MCI, and Pr-AD scored significantly lower
than S-MCI in MMSE, CVLT scores (short and long
delay recall, both free and cued), category fluency and
Frontal Battery Assessment (FAB). As expected, ApoE
e4 allele was much more frequent in Pr-AD than in S-
MCI. Conversely, active smoking and history of previous
stroke were more frequent in S-MCI than Pr-AD, and
S-MCI subjects scored slightly higher in Hamilton Rat-
ing Scale for depression. In our multivariate analysis,
CVLT long delay total recall score (CVLT-LDTR) and
MMSE turned out to be the only two variables indepen-
dently associated to Pr-AD. In order to assess their dis-
criminative power, we performed a ROC curve analysis
that showed an area under the curve of 0.773 for
MMSE (95% CI = 0.674-0.873, P < 0.001) and 0.775 for
CVLT-LDTR (95% CI = 0.689-0.861, P < 0.001). The
optimal thresholds for MMSE and CVLT-to predict pro-
gression from MCI to early AD were 26.5/30 and 4.5/16
respectively: those subjects that scored above 26/30 on
MMSE and 4/16 on CVLT-LDTR had a negative predic-
tive value of 93.93% at 2 years; inversely, those scoring
below on both tests had a positive predictive value of
80.95%. For those subjects with just only one test below
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be done as misclassifications were frequent. APOE ε4
status did not reach statistical significance (P = 0.168)
when it was added to the multivariate predictive model.
Discussion
As a whole, our progression rate is approximately 25%
per year, within the range of conversion from MCI to
AD previously reported [2,5,6,8-11]. In contrast with the
literature indicating that md-MCI is the subgroup with
the higher progression rate to dementia and that pure
amnestic forms have lower rates of progression
[6,10,12-14], in our series MCI of the amnestic type
(regardless of other cognitive domains impairment)
showed the higher risk of progression to dementia, with
approximately 60% evolving to dementia during the 2
years follow-up. Amyloid imaging in MCI subtypes [15]
showed that the highest proportion (approximately 80%)
of amyloid-positive patients belonged to the md-MCI
subgroup, although nearly 50% of a-MCI subjects were
also amyloid-positive, thus reflecting subjacent AD
pathology in a high proportion of a-MCI cases. There-
fore, not only md-MCI but also a-MCI should be con-
sidered as high-risk of progression to dementia
subgroups, and this is specially valid for those subjects
with a poorer memory performance.
MMSE and CVLT-LDTR were the only measures that
arose from multivariate analysis as independently asso-
ciated with progression risk from MCI to early AD.
According to our results, subjects scoring below 26/30
on MMSE and 4/16 on CVLT-LDTR constitute a MCI
subgroup at high risk of progressing to early AD.
MMSE is one of the most used tests for screening of
cognitive impairment worldwide, and it has been
Table 1 Comparison between prodromal AD and stable MCI according to baseline clinical and neuropsychological
features
Pr-AD n = 50 S-MCI n = 55 p-value Pr-AD n = 50 S-MCI n = 55 p-value
Age 75.94 (6.05) 72.93 (7.30) 0.021 MMSE 25.92 (1.88) 27.78 (1.55) < 0.001
Sex (% female) 59.37 64.58 0.575 WAT 16.87 (6.61) 17.32 (7.96) 0.778
Hamilton 3.92 (3.36) 6.32 (5.98) 0.033 Symbol-Digit 23.21 (10.86) 27.02 (10.86) 0.142
IDDD 41.09 (7.48) 38.11 (4.62) 0.071 CVLT-SDFR 1.52 (2.00) 4.55 (3.90) < 0.001
Hachinski 1.97 (1.15) 2.27 (1.72) 0.373 CVLT-SDTR 3.78 (2.40) 6.45 (3.32) < 0.001
Social extraction (% urban) 74.35 69.38 0.712 CVLT-LDFR 1.38 (1.86) 4.83 (4.03) < 0.001
Marital status (% married) 56.41 71.42 0.143 CVLT-LDTR 3.29 (2.42) 6.58 (3.42) < 0.001
Education (% primary school) 66.66 71.42 0.775 CVLT- Learning 12.83 (2.89) 13.77 (2.17) 0.054
HBP (%) 45.83 32.81 0.161 BNT 8.13 (2.58) 8.42 (2.46) 0.544
DM (%) 16.66 23.43 0.380 Rey figure copy 25.39 (10.71) 26.97 (9.00) 0.398
Smoking (% active) 6.25 25.00 0.009 WAIS block design 17.90 (8.24) 20.63 (7.89) 0.112
Alcohol (% active) 8.33 12.5 0.480 Stroop Test (interference) -7.36 (8.32) -5.71 (6.24) 0.233
Hypercholesterolemia (%) 33.33 31.25 0.815 TMT-A 111.05 (79.87) 88.38 (46.45) 0.083
Statins (%) 16.66 15.62 0.882 TMT-B 237.06 (120.56) 196.20 (98.85) 0.098
Ischemic cardiopathy (%) 4.16 10.93 0.192 Category fluency 10.88 (4.33) 12.87 (3.98) 0.017
Previous Stroke (%) 0 9.37 0.029 Phonemic fluency 5.89 (3.10) 6.98 (3.54) 0.099
Arterial ischemia (%) 0 1.56 0.384 FAB 12.94 (2.15) 14.44 (2.45) 0.004
Family History of Dementia (%) 31.25 28.12 0.720
ApoE E4 carrier (%) 53.48 28.30 0.012
Values are means (SD); p-value from univariate analysis, and in bold, those p-values which remained significant after the multivariate analysis adjusting for all
associated variables plus age, sex and ApoeE e4 status; Pr-AD (prodromal AD): MCI patients that progressed to AD during the follow-up; S-MCI (stable MCI): MCI
patients that did not progress to dementia; IDDD: Interview for Deterioration in Daily living activities in Dementia; HBP: High Blood Pressure; DM: Diabetes
Mellitus; WAT: Word Accentuation Test; CVLT: California Verbal Learning Test; SDFR: Short Delayed Free Recall; SDTR: Short Delayed Total Recall (free and cued);
LDFR: Long Delayed Free Recall; LDTR: Long Delayed Total Recall (free and cued); BNT: Boston Naming Test; TMT-A: Trail Making Test part A; TMT-B: Trail Making
Test part B; FAB: Frontal Assessment Battery.
Table 2 Sensitivity, specifity, PPV and NPV of MMSE and CVLT-LDTR for predicting AD
n = 105 Sensitivity (%) Specificity (%) PPV (%) NPV (%)
MMSE ≤ 26 64.10 79.59 71.42 73.58
CVLT-LDTR ≤ 4 72.91 70.31 64.81 77.58
MMSE ≤ 26 and/or CVLT-LDTR ≤ 4 94.80 63.26 67.27 93.93
MMSE ≤ 26 and CVLT-LDTR ≤ 4 43.58 91.83 80.95 67.16
PPV: positive predictive value; NPV: negative predictive value; CVLT-LDTR: California Verbal LearningTest Long Delayed Total Recall.
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three years before the diagnosis of dementia [16]. Other
tests used to determine general cognitive status (ADAS-
cog, Addenbrooke’s Cognitive Examination) have been
reported as good predictors, independently [9] or asso-
ciated with other neuropsychological measures [5,12];
however, these tests are not used so widespread in gen-
eral neurology clinics. Episodic memory tests have been
widely described as good predictors for AD in MCI sub-
jects, although usually they lacked specificity [17]. Sev-
eral types of memory test have been used [2-6,12,18],
but comparisons between them are limited [17]. The
long delay scores of verbal episodic memory tests that
are based on learning across multiple trials (i.e. CVLT)
seemed to provide the most sensitive index for initial
diagnosis of MCI and for detecting subjects which most
likely will evolve to AD, as their performance is highly
dependent on entorhinal and hippocampal systems [17].
The amnestic syndrome of the hippocampal type
described in AD [1] is specifically characterized by a
decreased total recall due to little effect of cueing. This
feature differs from that seen in frontotemporal demen-
tia, vascular dementia, other causes of fronto-subcortical
dementia and psychiatric diseases, such as depression,
that usually benefit from cueing. Therefore, CVLT-
LDTR is more sensitive to detect Pr-AD than other
CVLT scores because it captures the characteristic AD
amnestic syndrome. Semantic memory (measured
usually with category fluency) and attention and execu-
tive functions (measured usually with TMT-A or Sym-
bol Digit Modalities Test) have been described as
predictors of clinical progression in several studies
[5-7,13,19], mainly when combined with other episodic
memory scores or general cognitive assessments. How-
ever, in our multivariate analysis, category fluency and
FAB lost significance, indicating they did not add infor-
mation to that given by MMSE and CVLT-LDTR.
Conclusions
Pr-AD might be distinguished from S-MCI at baseline
using the combination of MMSE and CVLT-LDTR. The
clinical relevance of the findings is that these two neu-
ropsychological predictors are relatively brief and may
be readily completed in non-specialist clinical settings
(where CSF biomarkers, MRI or PET are not available).
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